Rhapontigenin inhibited hypoxia inducible factor 1 alpha accumulation and angiogenesis in hypoxic PC-3 prostate cancer cells

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 6, 2011, Pages 850-855

  Jung, Deok Beom ^a   Lee, Hyo Jeong ^a   Jeong, Soo Jin ^a   Lee, Hyo Jung ^a   Lee, Eun Ok ^a   Kim, Young Chul ^a   Ahn, Kyoo Seok ^a   Chen, Chang Yan ^b   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Hypoxia inducible factor 1 alpha; Prostate cancer; Rhapontigenin; Von Hippel Lindau protein

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOHEXIMIDE; DIMETHYLOXALYLGLYCINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; OXYGENASE INHIBITOR; RESVERATROL; RHAPONTIGENIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FIBROSARCOMA; GRAPE; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOPRECIPITATION; MALE; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; VITIS COIGNETIAE;

AMINO ACIDS, DICARBOXYLIC; ANGIOGENESIS INHIBITORS; CARCINOMA; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROCOLLAGEN-PROLINE DIOXYGENASE; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79957976474     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.850     Document Type: Article

References (37)

1. Dewhirst M. W., Cao Y., Moeller B., Nat. Rev. Cancer, 8, 425-437 (2008).
2. Bertout J. A., Patel S. A., Simon M. C., Nat. Rev. Cancer, 8, 967-975 (2008).
3. Kaelin W. G. Jr., Nat. Rev. Cancer, 8, 865-873 (2008).
4. Ji Q., Burk R. D., Biochem. Cell Biol., 86, 227-234 (2008).
5. Ferrara N., Gerber H. P., LeCouter J., Nat. Med., 9, 669-676 (2003).
6. Zhong H., De Marzo A. M., Laughner E., Lim M., Hilton D. A., Zagzag D., Buechler P., Isaacs W. B., Semenza G. L., Simons J. W., Cancer Res., 59, 5830-5835 (1999).
7. Park J. W., Chun Y. S., Kim M. S., J. Pharmacol. Sci., 94, 221-232 (2004).
8. Semenza G. L., Genes Dev., 14, 1983-1991 (2000).
9. Roupe K. A., Remsberg C. M., Yañez J. A., Davies N. M., Curr. Clin. Pharmacol., 1, 81-101 (2006).
10. Zhang R., Kang K. A., Piao M. J., Lee K. H., Jang H. S., Park M. J., Kim B. J., Kim J. S., Kim Y. S., Ryu S. Y., Hyun J. W., J. Toxicol. Environ. Health A, 70, 1155-1166 (2007).
11. Kim J. K., Kim N., Lim Y. H., J. Microbiol. Biotechnol., 20, 82-87 (2010).
12. Chun Y. J., Ryu S. Y., Jeong T. C., Kim M. Y., Drug Metab. Dispos., 29, 389-393 (2001).
13. Roupe K. A., Helms G. L., Halls S. C., Yañez J. A., Davies N. M., J. Pharm. Pharm. Sci., 8, 374-386 (2005).
14. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R., J. Clin. Invest., 52, 2745-2756 (1973).
15. Won S. H., Lee H. J., Jeong S. J., Lee H. J., Lee E. O., Jung D. B., Shin J. M., Kwon T. R., Yun S. M., Lee M. H., Choi S. H., Lu J., Kim S. H., Biol. Pharm. Bull., 33, 1828-1834 (2010).
16. Ahn Q., Jeong S. J., Lee H. J., Kwon H. Y., Han I., Kim H. S., Lee H. J., Lee E. O., Ahn K. S., Jung M. H., Zhu S., Chen C. Y., Kim S. H., Cancer Lett., 298, 212-221 (2010).
17. Park K. Y., Lee H. J., Jeong S. J., Lee H. J., Kim H. S., Kim S. H., Lim S., Kim H. C., Lü J., Kim S. H., Biol. Pharm. Bull., 33, 1835-1840 (2010).
18. Wang G. L., Semenza G. L., J. Biol. Chem., 270, 1230-1237 (1995).
19. Wu H., Liang X., Fang Y., Qin X., Zhang Y., Liu J., Biomed. Pharmacother., 62, 613-621 (2008).
20. Zhang Q., Tang X., Lu Q. Y., Zhang Z. F., Brown J., Le A. D., Mol. Cancer Ther., 4, 1465-1474 (2005).
21. Cao Z., Fang J., Xia C., Shi X., Jiang B. H., Clin. Cancer Res., 10, 5253-5263 (2004).
22. McNeill L. A., Hewitson K. S., Claridge T. D., Seibel J. F., Horsfall L. E., Schofield C. J., Biochem. J., 367, 571-575 (2002).
23. Bedard K., Krause K. H., Physiol. Rev., 87, 245-313 (2007).
24. Lee C. H., Jeong S. J., Yun S. M., Kim J. H., Lee H. J., Ahn K. S., Won S. H., Kim H. S., Lee H. J., Ahn K. S., Zhu S., Chen C. Y., Kim S. H., Proteome Sci., 8, 67 (2010).
25. Yu F., White S. B., Zhao Q., Lee F. S., Proc. Natl. Acad. Sci. U.S.A., 98, 9630-9635 (2001).
26. Zhang J., Li L., Kim S. H., Hagerman A. E., Lü J., Pharm. Res., 26, 2066-2080 (2009).
27. Harris A. L., Nat. Rev. Cancer, 2, 38-47 (2002).
28. Huang L. E., Gu J., Schau M., Bunn H. F., Proc. Natl. Acad. Sci. U.S.A., 95, 7987-7992 (1998).
29. Maxwell P. H., Semin. Cell Dev. Biol., 16, 523-530 (2005).
30. Mirzoeva S., Kim N. D., Chiu K., Franzen C. A., Bergan R. C., Pelling J. C., Mol. Carcinog., 47, 686-700 (2008).
31. Schoppmann S. F., Fenzl A., Schindl M., Bachleitner-Hofmann T., Nagy K., Gnant M., Horvat R., Jakesz R., Birner P., Breast Cancer Res. Treat., 99, 135-141 (2006).
32. Song Y., Wang W., Qu X., Sun S., Indian J. Med. Res., 129, 154-163 (2009).
33. Jung J. E., Lee H. G., Cho I. H., Chung D. H., Yoon S. H., Yang Y. M., Lee J. W., Choi S., Park J. W., Ye S. K., Chung M. H., FASEB J., 19, 1296-1298 (2005).
34. Shankar J., Thippegowda P. B., Kanum S. A., Biochem. Biophys. Res. Commun., 387, 223-228 (2009).
35. Yao H., Wang H., Zhang Z., Jiang B. H., Luo J., Shi X., Int. J. Cancer, 123, 1255-1261 (2008).
36. Semenza G. L., Nat. Rev. Cancer, 3, 721-732 (2003).
37. Kamba T., McDonald D. M., Br. J. Cancer, 96, 1788-1795 (2007).